Other
Transposition of the Great Arteries
3
Pipeline Programs↗
0
Active Trials↗
2
Companies Involved↗
Transposition of the Great Arteries is an early-stage landscape with 3 programs across 2 companies. The most active players are Orion Corporation, Orion Pharma, Eli Lilly. 1 therapy is approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 1
No programs
Phase 3
No programs
Approved1
Analysis
Trial Status
2
clinical trials
Unknown status1 · 50%
Completed1 · 50%
Clinical Trials
Trial Activity
Levosimendan Administration in Neonates With Transposition of the Great Arteries
Completed·—·Phase 2·NCT01120106·63 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)